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Triethylenetetramine tetrahydrochloride
(trientine tetrahydrochloride; Cuprior)
• First reported in 1920
• Crystalline solid mp 266-270 °C
• Prepared by addition of HCl to triethylenetetramine
• Not reported to be hygroscopic
• Cu2+ coordination noted in 1936
Trientine (triethylenetetramine) structures
Cuprior (GMP-Orphan: trientine.4HCl)
150 mg free base/tablet 
cost/tablet: 25p/mg (free base)
trientine free base (Tosoh, Japan)*
cost (technical grade): ~ 0.0006p/mg
Cufence (Univar: trientine.2HCl)
200 mg free base/capsule
cost/capsule: 15p/mg (free base)
*Quotation from Henan Tianfu Chemical Co., China 
Cuprior 150 mg tablets
• Stable at room temperature; do not require refrigeration
• 16 mm x 8 mm − each tablet dividable into equal doses
• Recommended adult dose: 3−6½ tablets/day
• 6 x Cuprior tablets/day  0.9 grams chloride ion
[Dietary chloride ion intake = 2 grams/day]
Cuprior: 150 mg base  300 mg trientine.4HCl; Cufence: 200 mg base  300 mg trientine.2HCl
GMP-Orphan − EMA submission data (2015)
Cuprior tablets compared with Cufence capsules
Dissolution
• Faster aqueous dissolution (pH 1.2; pH 4.0 and pH 6.8)
• Ascribed to differences in formulation rather than solubility differences 
between the two salts 
Bioavailablity 
• Higher bioavailability cf. Cufence (pharmacokinetic data)
• Approx. 60% dose adjustment factor proposed to provide daily dose 
of trientine free base equivalent to that from the dihydrochloride
Bioavailability of Cuprior and Cufence
Relative bioavailabilities determined by:
• Aqueous solubility and dissolution
• Protonation of trientine base (bis-protonated at pH 6-7; 
tetra-protonated at pH 2-3)
• pH of gastric acid (pH 1.5 to 3.5) 
• pH of intestinal tract (pH 6 to 7.4) 
Bioavailability of Cuprior and Cufence
Conclusions:
• The speciation of trientine in vivo will be the same irrespective of the 
administration of the dihydrochloride or the tetrahydrochloride 
• Once in the intestinal tract, the subsequent absorption, distribution 
and metabolism of the two drugs will also be equivalent
Therefore:
Relative bioavailability of trientine is determined by aqueous 
solubility/dissolution of the formulated salt
Cuprior: clinical trial
Trientine tetrahydrochloride (TETA.4HCl) for the treatment of 
Wilson’s disease
• ClinicalTrials.gov Identifier: NCT03539952
• Participating countries: Belgium, Brazil, Denmark, France, 
Germany, Italy, Poland, Sweden, UK and USA
• Completion date: November 2021
https://www.clinicaltrials.gov/ct2/show/NCT03539952
